Company / Operating Cash Flow
NovoCure Ltd Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$49.0M
FY2025
5-year range
-$73.3M / $82.8M
FY2021-FY2025
Trend
-85.9%
vs FY2024
Sector context
#143 of 158
Health Care
What the data says
Among 158 Health Care companies, NovoCure Ltd is in the bottom 9% for operating cash flow. Operating Cash Flow has fluctuated over the past 10 years, ranging from -$108M in FY2016 to $99M in FY2020.
Based on SEC 10-K filings.
-$49M in FY2025.
Improved from -$73M to -$49M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 158This company -$49.0M Sector average $1.0B
▼
-104.7% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow decreased 85.9% year-over-year.
- Ranks #143 out of 158 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2020.
- Lowest operating cash flow in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -0.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$49.0M | -85.9% |
| FY2024 | -$26.4M | +64.0% |
| FY2023 | -$73.3M | -338.2% |
| FY2022 | $30.8M | -62.8% |
| FY2021 | $82.8M | -16.5% |
| FY2020 | $99.1M | +272.5% |
| FY2019 | $26.6M | +1527.3% |
| FY2018 | -$1.9M | +94.4% |
| FY2017 | -$33.1M | +69.2% |
| FY2016 | -$107.6M | -7.7% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026